Proton Beam Therapy for Localized Prostate Cancer: Results from a Prospective Quality-of-Life Trial.

ABSTRACT:

Purpose

To report prostate cancer outcomes, toxicity, and quality of life (QOL) in men treated with proton beam therapy (PBT).

Patients and methods

Patients were enrolled in a prospective trial. All participants received 75.6 to 78 Gy (RBE). Up to 6 months of luteinizing hormone-releasing hormone agonist therapy was allowed. The Phoenix definition defined biochemical failure. Modified Radiation Therapy Oncology Group criteria defined toxicity. Expanded Prostate Cancer Index Composite questionnaires objectified QOL. Clinically significant QOL decrement was defined as ≥0.5 × baseline standard deviation.

Results

In total, 423 men were analyzed. The National Comprehensive Cancer Network risk classification was used (low 43%; intermediate 56%; high 1%). At the 5.2-year med

SUBMITTER: Pugh TJ 

PROVIDER: S-EPMC6871578 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature